Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.
about
Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets.Heparin-coated cardiopulmonary bypass circuits: current status.Complement depletion accelerates the clearance of immune complexes from the circulation of primates.Significant changes in the levels of secreted cytokines in brains of experimental antiphospholipid syndrome miceStructural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group.Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits.Overall sulfation of heparan sulfate from pancreatic islet β-TC3 cells increases maximal fibril formation but does not determine binding to the amyloidogenic peptide islet amyloid polypeptideExcessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.Complement inhibition keeps mothers calm and avoids fetal rejection.Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma.Complement activation during hemodialysis.Proteoglycans in health and disease: structures and functions.Oxidative degradation of rat mast-cell heparin proteoglycan.Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.Interaction of poly(styrene sulfonic acid) with the alternative pathway of the serum complement system.Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin.Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass.
P2860
Q33883732-D901CEEE-573E-485F-94EB-1941208759BFQ34375503-BD422814-6344-489E-9E27-4FA7CEBE8CCDQ34617128-8E489D48-6DA9-4C99-8D5C-E6D5F11611BEQ35791670-70450535-2E0B-4BDB-A9A7-EB8BB05DFB8BQ36214990-6AEF9571-753B-4897-B7F7-7F47822418ADQ36330416-48F0AA17-2252-4F40-8BE7-116955B9CB87Q36347775-B0830818-E40D-4F5A-BD04-1A857E09CD7BQ36470411-8C54476F-F804-4836-BCB4-4F179152145EQ37248466-2ACDF5DB-7884-496A-B257-E6DA1A0971B5Q38337031-CB99EA45-427A-4DB9-A1B3-31CC903B81CAQ38698334-0C91CAC7-B1BE-4F91-9DB7-5E112CA9C111Q39750946-F46276FD-E37D-490E-B693-B1E901E3976EQ42859290-3753A8C0-94EE-4B94-9F91-E5FD18496028Q45111033-EF23CDE5-813E-4C9D-9DCB-7F7C3463B254Q46454257-D54DF66D-3507-4498-9311-B27E57A0897AQ47232832-2A68D8A7-28B8-4B44-A234-A56C2C5C9539Q50984141-52B13054-2178-4EA0-B51C-33E6FDF32E41
P2860
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1981
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Structural determinants of the ...... n amplification C3 convertase.
@en
Structural determinants of the ...... n amplification C3 convertase.
@nl
type
label
Structural determinants of the ...... n amplification C3 convertase.
@en
Structural determinants of the ...... n amplification C3 convertase.
@nl
prefLabel
Structural determinants of the ...... n amplification C3 convertase.
@en
Structural determinants of the ...... n amplification C3 convertase.
@nl
P2093
P2860
P356
P1476
Structural determinants of the ...... n amplification C3 convertase.
@en
P2093
D D Metcalfe
D T Fearon
K F Austen
M D Kazatchkine
R D Rosenberg
P2860
P304
P356
10.1172/JCI110017
P407
P577
1981-01-01T00:00:00Z